Recently, Pharma Sources conducted an exclusive interview with Dr. Fang Yongliang, Chief Operating Officer of Doer Biologics, at the CPHI & PMEC China 2026 exhibition site, where he elaborated on the technological innovations and commercialization strategies of the triple agonist DR10624.

Below is the link to the interview: https://mp.weixin.qq.com/s/qgXao-f7YAiwskAHdqSaoA?scene=1&click_id=1